Crinetics Pharmaceuticals has been granted a patent for compounds that modulate somatostatin activity, suppressing secretion of various hormones in mammals. The method involves administering these compounds for treating conditions that would benefit from somatostatin modulation. GlobalData’s report on Crinetics Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Crinetics Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Crinetics Pharmaceuticals's grant share as of January 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11834462B2) discloses a method for suppressing the secretion of various hormones such as growth hormone (GH), insulin, glucagon, insulin-like growth factor 1 (IGF-1), prolactin, or combinations thereof in mammals. The method involves administering a therapeutically effective amount of a compound with specific structures to the mammal in need. The patent claims cover different structures of compounds that can be used for this purpose, providing a detailed framework for modulating hormone secretion in mammals.
Furthermore, the patent also includes a method for modulating somatostatin receptor subtype 2 (SSTR2) activity in mammals by administering a therapeutically effective amount of a compound with specific structures. The disclosed method offers a way to regulate the activity of SSTR2 in mammals, including humans, dogs, and cats. By specifying the structures of compounds that can be used for this purpose, the patent provides a comprehensive guide for modulating SSTR2 activity in different mammalian species. Overall, the patent offers valuable insights into hormone secretion suppression and SSTR2 modulation, potentially opening up new avenues for therapeutic interventions in various conditions related to hormone dysregulation.
To know more about GlobalData’s detailed insights on Crinetics Pharmaceuticals, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
